Dr. Johnathon Liddicoat and his team at King’s College London have uncovered a quiet revolution unfolding in hospital basements and university labs across the globe—where a breast cancer drug is being tested to prevent the disease, an anti-inflammatory once used for arthritis is fighting COVID-19, and a cancer therapy is restoring sight in patients facing blindness. This isn’t science fiction; it’s the growing world of drug repurposing, a parallel innovation system operating outside the high-stakes, high-cost pharmaceutical industry. And it’s doing so at up to 90% lower cost.
While big pharma focuses on patent-driven profits, universities and hospitals are quietly running late-stage clinical trials on generic drugs—medicines whose patents have expired and whose prices have plummeted. These institutions aren’t chasing shareholder returns; they’re driven by patient outcomes and scientific curiosity. The result? A hidden pipeline of affordable treatments that could reshape global access to medicine. The Cambridge Law Journal recently published findings showing that these non-industry trials are funded at less than 10% of the cost reported by pharmaceutical companies, unlocking life-saving potential without the financial barriers.
The economics make sense: repurposed drugs bypass the most expensive phases of development. They’re already manufactured, their safety profiles are well-documented, and researchers can build on decades of data. This slashes the three biggest hurdles in drug innovation—expertise, risk, and capital. When a hospital team in Belgium tests aspirin-like drugs for viral infections or a London clinic explores tamoxifen’s preventive potential, they do so with grant funding, ethical oversight, and a mission to publish and heal—not profit. As Dr. Liddicoat notes, “no organization's financial viability depends on the authorization and sales of the drug,” freeing scientists to pursue high-impact, low-reward therapies that industry ignores.
And the timing couldn’t be more critical. Once a drug goes generic, pharmaceutical companies abandon further research—there’s no profit in it. But that’s exactly when academic and clinical teams step in. Where industry sees dead ends, they see second chances. With over 32 new uses approved annually during a drug’s patent life, the untapped potential in expired-patent medicines is vast. Now, governments are taking notice, launching programs to formally recognize and fund this overlooked ecosystem.
This isn’t just about saving money—it’s about democratizing medical progress. When a drug that once cost thousands becomes a widely accessible tool for new treatments, entire health systems benefit. The future of medicine may not come from a corporate lab, but from a clinician’s insight and a generic pill sitting in a hospital pharmacy. As this alternative system gains recognition, it offers a hopeful blueprint: innovation guided not by patents, but by patients.